{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:54:32Z","timestamp":1789167272509,"version":"build-2803163510"},"reference-count":22,"publisher":"China Science Publishing & Media Ltd.","issue":"2","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2022,2,1]]},"DOI":"10.3724\/abbs.2022008","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T04:36:19Z","timestamp":1644381379000},"page":"252-260","update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":10,"title":["SY-707, an ALK\/FAK\/IGF1R inhibitor, suppresses growth and metastasis of breast cancer cells"],"prefix":"10.3724","volume":"54","author":[{"given":"Ping","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xijie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoyun","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"Siegel RL","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin, 2019, 69: 7-34.","journal-title":"CA Cancer J Clin"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrc1670","volume":"5","author":"Weigelt B","year":"2005","unstructured":"Weigelt B, Peterse JL, van\u2032t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer, 2005, 5: 591-602.","journal-title":"Nat Rev Cancer"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3389\/fonc.2018.00227","volume":"8","author":"Tong CWS","year":"2018","unstructured":"Tong CWS, Wu M, Cho WCS, To KKW. Recent advances in the treatment of breast cancer. Front Oncol, 2018, 8:","journal-title":"Front Oncol"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1369\/0022155414561498","volume":"63","author":"Yoon H","year":"2015","unstructured":"Yoon H, Dehart JP, Murphy JM, Lim STS. Understanding the roles of FAK in cancer. J Histochem Cytochem, 2015, 63: 114-128.","journal-title":"J Histochem Cytochem"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2174\/187152011796817619","volume":"11","author":"M. Golubovskaya V","year":"2011","unstructured":"M. Golubovskaya V, G. Cance W. FAK and p53 protein interactions. ACAMC, 2011, 11: 617-619.","journal-title":"ACAMC"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s10549-018-5043-0","volume":"174","author":"Shtam T","year":"2019","unstructured":"Shtam T, Naryzhny S, Samsonov R, Karasik D, Mizgirev I, Kopylov A, Petrenko E. Plasma exosomes stimulate breast cancer metastasis through surface interactions and activation of FAK signaling. Breast Cancer Res Treat, 2019, 174: 129-141.","journal-title":"Breast Cancer Res Treat"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13058-015-0551-x","volume":"17","author":"Tancioni I","year":"2015","unstructured":"Tancioni I, Miller NLG, Uryu S, Lawson C, Jean C, Chen XL, Kleinschmidt EG. FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth. Breast Cancer Res, 2015, 17:","journal-title":"Breast Cancer Res"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1186\/1471-2407-14-769","volume":"14","author":"Golubovskaya VM","year":"2014","unstructured":"Golubovskaya VM, Ylagan L, Miller A, Hughes M, Wilson J, Wang D, Brese E. High focal adhesion kinase expression in breast carcinoma is associated with lymphovascular invasion and triple-negative phenotype. BMC Cancer, 2014, 14:","journal-title":"BMC Cancer"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.pharmthera.2014.10.001","volume":"146","author":"Lee BY","year":"2015","unstructured":"Lee BY, Timpson P, Horvath LG, Daly RJ. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther, 2015, 146: 132-149.","journal-title":"Pharmacol Ther"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/13543776.2018.1414183","volume":"28","author":"Lv PC","year":"2018","unstructured":"Lv PC, Jiang AQ, Zhang WM, Zhu HL. FAK inhibitors in Cancer, a patent review. Expert Opin Therapeutic Patents, 2018, 28: 139-145.","journal-title":"Expert Opin Therapeutic Patents"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nrc3792","volume":"14","author":"Sulzmaier FJ","year":"2014","unstructured":"Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer, 2014, 14: 598-610.","journal-title":"Nat Rev Cancer"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrc1647","volume":"5","author":"McLean GW","year":"2005","unstructured":"McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. The role of focal-adhesion kinase in cancer \u2014 a new therapeutic opportunity. Nat Rev Cancer, 2005, 5: 505-515.","journal-title":"Nat Rev Cancer"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/1535-7163.MCT-11-0261","volume":"10","author":"Stokes JB","year":"2011","unstructured":"Stokes JB, Adair SJ, Slack-Davis JK, Walters DM, Tilghman RW, Hershey ED, Lowrey B. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther, 2011, 10: 2135-2145.","journal-title":"Mol Cancer Ther"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1158\/0008-5472.CAN-07-5155","volume":"68","author":"Roberts WG","year":"2008","unstructured":"Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, Richter D. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res, 2008, 68: 1935-1944.","journal-title":"Cancer Res"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10549-014-3230-1","volume":"149","author":"Green AR","year":"2015","unstructured":"Green AR, Caracappa D, Benhasouna AA, Alshareeda A, Nolan CC, Macmillan RD, Madhusudan S. Biological and clinical significance of PARP1 protein expression in breast cancer. Breast Cancer Res Treat, 2015, 149: 353-362.","journal-title":"Breast Cancer Res Treat"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1517\/13543784.2010.489548","volume":"19","author":"Schultze A","year":"2010","unstructured":"Schultze A, Fiedler W. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opin Investig Drugs, 2010, 19: 777-788.","journal-title":"Expert Opin Investig Drugs"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/BF00121193","volume":"1","author":"Milas L","year":"1983","unstructured":"Milas L, Peters LJ, Ito H. Spontaneous metastasis: random or selective?. Clin Exp Metast, 1983, 1: 309-315.","journal-title":"Clin Exp Metast"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0163-7258(02)00179-1","volume":"93","author":"Fabbro D","year":"2002","unstructured":"Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther, 2002, 93: 79-98.","journal-title":"Pharmacol Ther"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S1471-4914(01)02217-1","volume":"8","author":"Zwick E","year":"2002","unstructured":"Zwick E, Bange J, Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med, 2002, 8: 17-23.","journal-title":"Trends Mol Med"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.critrevonc.2003.08.004","volume":"50","author":"Bennasroune A","year":"2004","unstructured":"Bennasroune A, Gardin A, Aunis D, Cr\u00e9mel G, Hubert P. Tyrosine kinase receptors as attractive targets of cancer therapy. Crit Rev Oncol Hematology, 2004, 50: 23-38.","journal-title":"Crit Rev Oncol Hematology"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/cancers11010105","volume":"11","author":"Liu CY","year":"2019","unstructured":"Liu CY, Chu PY, Huang CT, Chen JL, Yang HP, Wang WL, Lau KY. Varlitinib downregulates her\/erk signaling and induces apoptosis in triple negative breast cancer cells. Cancers, 2019, 11:","journal-title":"Cancers"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.canlet.2009.07.005","volume":"289","author":"Luo M","year":"2010","unstructured":"Luo M, Guan JL. Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis. Cancer Lett, 2010, 289: 127-139.","journal-title":"Cancer Lett"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/engine.scichina.com\/doi\/pdf\/02B5C833F254497DAEB6A390166FA547","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/engine.scichina.com\/doi\/10.3724\/abbs.2022008","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/engine.scichina.com\/doi\/pdf\/02B5C833F254497DAEB6A390166FA547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T12:25:17Z","timestamp":1652963117000},"score":1,"resource":{"primary":{"URL":"https:\/\/engine.scichina.com\/doi\/10.3724\/abbs.2022008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,10]]},"published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.3724\/abbs.2022008","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-148993\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-148993\/v1","asserted-by":"object"}]},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,1]]}}}